KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
DMA 100DMA 200DMA 50Dividend YieldEV to CFOEV to EBITEV to EBITDAEV to FCFEV to RevenueEnterprise ValueMarket Cap to FCFMarket CapitalizationPricePrice to EarningsPrice to Sales
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Jazz Pharmaceuticals (JAZZ) Enterprise Value (2016 - 2025)

Jazz Pharmaceuticals has reported Enterprise Value over the past 16 years, most recently at -$1.4 billion for Q4 2025.

  • Quarterly Enterprise Value rose 42.31% to -$1.4 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$1.4 billion through Dec 2025, up 42.31% year-over-year, with the annual reading at -$1.4 billion for FY2025, 42.31% up from the prior year.
  • Enterprise Value was -$1.4 billion for Q4 2025 at Jazz Pharmaceuticals, down from -$1.3 billion in the prior quarter.
  • Over five years, Enterprise Value peaked at -$490.8 million in Q1 2022 and troughed at -$2.4 billion in Q4 2024.
  • The 5-year median for Enterprise Value is -$1.3 billion (2023), against an average of -$1.3 billion.
  • Biggest five-year swings in Enterprise Value: tumbled 198.96% in 2021 and later soared 76.6% in 2022.
  • Tracing JAZZ's Enterprise Value over 5 years: stood at -$591.4 million in 2021, then plummeted by 49.04% to -$881.5 million in 2022, then plummeted by 70.88% to -$1.5 billion in 2023, then plummeted by 60.18% to -$2.4 billion in 2024, then surged by 42.31% to -$1.4 billion in 2025.
  • According to Business Quant data, Enterprise Value over the past three periods came in at -$1.4 billion, -$1.3 billion, and -$1.2 billion for Q4 2025, Q3 2025, and Q2 2025 respectively.